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Available online 2 February 2018Roux-en-Y Gastric bypass surgery (RYGB) is emerging as a powerful tool for treatment of obesity and may also
cause remission of type 2 diabetes. However, the molecular mechanism of RYGB leading to diabetes remission
independent ofweight loss remains elusive. In this study, we proﬁled plasmametabolites and proteins of 10 nor-
mal glucose-tolerant obese (NO) and 9 diabetic obese (DO) patients before and 1-week, 3-months, 1-year after
RYGB. 146 proteins and 128metabolites from both NO and DO groups at all four stages were selected for further
analysis. By analyzing a set of bi-molecular associations among the corresponding network of the subjects with
our newly developed computational method, we deﬁned the represented physiological states (called the edge-
states that reﬂect the interactions among the bio-molecules), and the related molecular networks of NO and
DO patients, respectively. The principal component analyses (PCA) revealed that the edge states of the post-
RYGB NO subjects were signiﬁcantly different from those of the post-RYGB DO patients. Particularly, the time-
dependent changes of the molecular hub-networks differed between DO and NO groups after RYGB. In conclu-
sion, by developing molecular network-based systems signatures, we for the ﬁrst time reveal that RYGB gener-
ates a unique path for diabetes remission independent of weight loss.






Network biomarkerThe plasma samples of normal glucose-tolerant obese (NO) and dia-
betic obese (DO) patients, before and after Roux-en-Y Gastric Bypass
(RYGB) surgery, were subjected to proteomic and metabolomic
analysis. With our newly developed computational method, we de-
ﬁned the physiological states based on bi-molecular associationstems Biology, CAS Center for
istry and Cell Biology, Shanghai
Sciences, 320 Yueyang Road,
dical Sciences, Faculty of Health
gen, Denmark.
st@sund.ku.dk (J.J. Holst),
pen access article under the CC BY-NC-NDamong proteins and metabolites (edges) instead of the concentra-
tions of those biomolecules (nodes) for each individual in each stage.
Based on integration of these multi-omics molecular networks, we
showed that RYGB generates a unique remission-path of type 2 dia-
betes independent of weight loss.1. Introduction
Roux-en-Y gastric bypass surgery (RYGB) used for treatment of obe-
sity has turned out to be often leading to apparent remission of diabetes
(Mosinski and Kirwan, 2016; Rubino et al., 2010; Vetter et al., 2009).
Based on the conceptions of reductionism, researchers have generally
tried to identify particular effectors in order to understand the diabeteslicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
235Q.-R. Li et al. / EBioMedicine 28 (2018) 234–240remission. Thus, a number of previous studies have identiﬁed individual
RYGB-induced effectors that may improve glucose homeostasis, such as
certain gut hormones (Jorgensen et al., 2013; Karamanakos et al., 2008),
metabolites (Baud et al., 2016; Gerhard et al., 2013; Patti et al., 2009),
and proteins (Ryan et al., 2014). On one hand, the regulations of these
molecules presumably are direct consequences of RYGB, for example,
the postprandial plasma concentrations of glucagon-like peptide-1
(GLP-1) and peptide YY (PYY) of obese patients were elevated already
2 days after RYGB (Saeidi et al., 2013). On the other hand, there is no ev-
idence that they (or some of them) also are themain effectors of diabe-
tes remission independentweight loss. Our previousworks have shown
that the postprandial GLP-1 secretion was increased more than 10-fold
after RYGB in both groups of obese patients with normal glucose toler-
ance and obese diabetic patients (Jorgensen et al., 2012). Furthermore,
other study has demonstrated that RYGB-induced changes of hormone
expressions such as ghrelin, secretin, GLP-1, PYY and glucagon in the
small-intestinal enteroendocrine cells, were quite similar across both
groups of obese patients with normal and abnormal glucose tolerance
(Rhee et al., 2015), implying that those RYGB-induced individual mole-
cules might be the only relevant effectors for diabetes remission.
From a systems biology point of view, type 2 diabetes is a complex
disease involving complicated interactions between many genes, pro-
teins and metabolites. Thus, it has been reported that the RYGB-
induced diabetes remission involves signiﬁcant alterations of plasma
metabolomic and lipidomic proﬁling (Hansen et al., 2013), implying
that global changes of the patient's biomoleculesmay be required for di-
abetes remission. In addition, several previous reports showed that the
surgery could generate signiﬁcant tissue changes such as increasing the
size and mass of gut wall (Hansen et al., 2013), and this rearranged gut
itself improved the glucose homeostasis (Saeidi et al., 2013). It should
also be noted that improvements in pancreatic beta-cell secretary ca-
pacity and in hepatic and peripheral insulin sensitivity are also major
regulators of glucose metabolism and remission of diabetes after RYGB
(Jorgensen et al., 2013; Bojsen-Moller et al., 2014).
In the present study, the plasma samples of normal glucose-tolerant
obese (NO) and diabetic obese (DO) patients, who were operated with
RYGB (Jorgensen et al., 2012), were subjected to proteomic and
metabolomic analysis by mass-spectrometry. With our newly devel-
oped computational method (Zhang et al., 2015), we deﬁned the repre-
sented bi-associations between plasma proteins and metabolites of
each subject. Based on these multi-omics molecular networks, we
show that RYGB generates a unique remission-path of type 2 diabetes
independent of weight loss.
2. Materials and Methods
Brieﬂy, plasma samples were collected from 10 normal glucose-
tolerant obese (NO) and 9 diabetic obese (DO) patients before and 1-
week, 3-months, 1-year after RYGB. At each stage, the plasma samples
were obtained at three time points for each individual, including the
fasting state and 30 min and 45 min after a standardized liquid meal
(Jorgensen et al., 2012). Signed informed consents from participants
were obtained, and the study protocol has been approved by ethical
committee. The collection procedures were conformed to standards in-
dicated by the Declaration of Helsinki.
For proteome proﬁling, the plasma proteins were removed high-
abundance proteins, in-solution digested, randomized labeled with
six-plex TMT reagents, and analyzed by high resolutionmass spectrom-
etry. Themetabolomeproﬁling involved non-targeted analysis, targeted
amino acid analysis and targeted acyl-carnitine analysis as well. Collec-
tively, 146 proteins and 128 metabolites were measured from both NO
and DO groups at all four stages, and used for bioinformatics analysis.
To illuminate the stage-wise data involved the molecular network,
the data structure were ﬁrstly rebuilt from node-state to edge-state.
After ﬁne-tuned neighborhood selection, the group similarity were cal-
culated and evaluated for group-temporal smoothed networkgeneration. Following model comparisons, regularization, and optimi-
zation, artiﬁcial data with known network structures were evaluated
in silico, and were further used to analyze the experimental data. Fi-
nally, the network and state were inspected for the inﬂuence by RYGB,
and distance and PCA analysis were performed to visualize the trajecto-
ries or routes of the state transitions from the RYGB for NO and DO sub-
jects, respectively.
Details regardingmethods, including experimentalmethods for pro-
teomics andmetabolomics analyses, as well as computational methods,
are available in the Supplementary information. Themass spectrometry
proteomics data have been deposited to the ProteomeX change Consor-
tium via the PRIDE (Vizcaino et al., 2016) partner repository with the
dataset identiﬁer PXD008071.3. Results
3.1. Computational Analysis of Edge-states Based on Bi-molecular Associa-
tions Among Plasma Proteins and Metabolites
Plasma samples from our previously described clinical cohort
(Jorgensen et al., 2012), 10 NO and 9 DO subjects obtained pre-RYGB,
1 week (1w), 3 months (3 m), and 1 year (1y) after RYGB (Jorgensen
et al., 2012), were included in this analysis. Plasma sampleswere obtained
at three time points for each individual, including the fasting state
and30minand45minafter a standardized liquidmeal (Fig. 1a). Signiﬁcant
decrease of fasting glucosewas observed in the DO group already 1w after
RYGB (Fig. 1b), but signiﬁcant declines of BMIwere not seen until 3m and
1 y after RYGB in both groups. This indicates that the early remission of di-
abetes observed in the DO group is independent of weight loss.
We applied proteomic and metabolomic analyses on those plasma
samples (Supplementary information). We quantiﬁed 146 plasma pro-
teins (Supplementary Table S1) and 128 metabolites (Supplementary
Table S2) that could be identiﬁed in all subjects at three time points
(fasting, postprandial 30 min and 45 min) of four stages (pre-RYGB,
post-RYGB at 1w, 3 m and 1y) (Fig. 1c). All 274 molecules were recog-
nized as nodes for composing the molecular networks.
We ﬁrst deﬁned pathological states of the subjects before and after
RYGB based on the concentrations of these molecular nodes and called
them node-states (Fig. 1d, left panel). Then we analyzed the relation-
ships among the node-states of the patients under various treatments
in all stages based on the plasma molecular concentrations of all
protein- and metabolite-nodes. By using Kruskal-Wallis test (Gregory
and Corder, 2009), we selected the “differential” nodes based on their
differential molecular concentrations at the four stages. Both hierarchi-
cal clustering analysis (HCA) and principal components analysis (PCA)
showed that the states of the patients were not clearly classiﬁed into
the corresponding phenotypes, and the stage-related changes of
patient-states were not presented (Fig. 2a and b). Interestingly, both
NO and DO individuals at 1w after RYGB (Fig. 2a, model I) were sepa-
rated from the pre-RYGB group and the groups at 3 m and 1y after
RYGB (Fig. 2a,model II), implying that the node-states derived from dif-
ferential node-concentration could demonstrate the changes of the sur-
gical stress rather than the changes of metabolic homeostasis.
In previous papers, we reported that the edge-state derived from all
edges of the network was insensitive to the perturbations (Zeng et al.,
2016; Zhang et al., 2015). Therefore we developed a computational
method Group-Temporal Lasso (GTLasso) to identify each subject's mo-
lecular network as well as all edges (Supplementary information),
which were in turn employed to characterize the subject's state,
i.e., the edge-state. Speciﬁcally, GTLasso transforms the node-state to
the corresponding edge-state for individual subject at each particular
stage by integrating omics data of time-series (three time-points in
this case: fasting, postprandial 30min and 45min) (Fig. 1a, and Supple-
mentary information). Note that an edge-state could be represented by
all edges or selected edge-biomarkers (network biomarkers) that are
Fig. 1.Workﬂow of systematic analysis on RYGB-treated subjects. (a) 10Non-diabetic Obese (NO) and 9 Diabetic Obese (DO)were subjected to RYGB. The plasma samples of each subject
on four stages (pre-RYGB, 1w, 3 m, and 1y after RYGB) were collected at three time points, including the fasting, postprandial 30 min and 45 min. (b) BMI and fasting glucose before and
after RYGB showed the signiﬁcant loss of weight in both group and decrease of fasting glucose in DO group. (c) Quantitative proteomic andmetabolic data were detected at all four stages
of each subject. (d) Sketch shows the computational methods to calculate molecular states either by nodes or by edges.
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markers (Zhang et al., 2015; Yu et al., 2017).3.2. RYGB Generates a Unique Remission-path of Type 2 Diabetes Indepen-
dent of Weight Loss
The HCA result based on calculation of edge-states showed that the
DO and NO were grouped together before the operation (Module I,
Fig. 2c), clearly separated from all stages after RYGB (Module II,
Fig. 2c), indicating that RYGB generated signiﬁcant changes of the phys-
iological states in both DO and NO subjects.
Furthermore, the PCA result based on the edge-states clearly dem-
onstrated that the DO and NO subjects presented different remission
paths after RYGB (Fig. 2d). Firstly, all the NO subjects were separated
from the DO subjects by PC1 (Fig. 2d), indicating that the NO edge-
states, composed of bi-associations among plasma proteins and metab-
olites, are signiﬁcantly different from the DO edge-states at both pre-
and after-RYGB stages. Secondly, in agreement with the ﬁndings that
there was no major weight loss at 1w after RYGB, but signiﬁcant and
continuous weight loss at 3 m and 1y after RYGB (Fig. 1b), both DO
and NO subjects at the stages of pre-RYGB and 1w after RYGB were
clearly separated from those at the stages of 3 m and 1y after RYGB by
PC2 (Fig. 2d), indicating that the soleweight loss is amajor factor to sep-
arate the subjects with higher BMI from the subjects with lower BMI.
Thirdly, consistent with our previous data that the NO subjects showed
dramatic improvement of hepatic insulin sensitivity at 1w after RYGB,
but more moderate changes at 3 m and 1y (Tables 1 and 2 of
Jorgensen et al., 2012), the NO subjects at 1w after surgery were sepa-
rated from the pre-RYGBNO subjects (Fig. 2d), whereas theNO subjects
at 3 m and 1y after RYGB were located in the same PC2-area (Fig. 2d).This suggests that the post-RYGBNO subjects at 3m and 1y have similar
edge-states due to the similar glucose homeostasis of these two groups.
Importantly, consistentwith the previous results about continuous im-
provement of glucose homeostasis of the DO subjects from 1w to 1y after
RYGB (e.g. continuously decreasing fasting plasma-glucose concentration;
Jorgensen et al., 2012), the PCA result showed that the edge-states of DO
subjects from pre-RYGB continuously moved away along PC2-axis at the
three stages of 1w, 3 m and 1y after RYGB (Fig. 2d). Taken together, PCA
analysis reveals that RYGB generates a unique remission-path of type 2 di-
abetes independent of weight loss, which involves extensive changes of
molecular associations among proteins and metabolites.
3.3. Molecular Hub-networks of DO and NO Subjects Were Differentially
Rewired After RYGB
We thereafter tried to answer the related questionwhat is difference
between the post-RYGB DO and NO molecular networks. Based on cal-
culating the molecular bi-associations among the detected plasma pro-
teins and metabolites by GTLasso approach, the molecular network
representing the time-dependent edges-state after RYGB could be con-
structed at every particular stage (Supplementary information). Since
the molecular hubs, which are connected with multiple molecules, are
considered themajor players in a particularmolecular network, we fur-
ther analyzed the hub-networks of both DO and NO subjects at all four
stages of the RYGB based on these constructed networks consisting of
plasma proteins and metabolites.
We showed that the NO and DO hub-networks at all four stages are
quite different (compare Fig. 3a–d, h–g). This is consistent with the PCA
result that all the edge-states of the NO subjects were separated from
that of the DO subjects by PC1 (Fig. 2d). Also, the hub-network of the
pre-RYGB NO subjects (Fig. 3a) was signiﬁcantly different from that of
Fig. 2. Individual state classiﬁcation using both proteomic andmetabolic data. (a, b) HCA and PCA based on differential nodes; (c, d) HCA and PCA based on all edges. Obviously, the edge-
states of the patients were clearly classiﬁed into the corresponding phenotypes.
237Q.-R. Li et al. / EBioMedicine 28 (2018) 234–240the pre-RYGBDO subjects (Fig. 3e): the formerwasmainly composed of
metabolites, which could be divided into one amino-acid sub-network
and one glycol-lipid sub-network (Fig. 3a), whereas the latter mainly
consisted of proteins (Fig. 3e). These results imply that the dysfunc-
tional metabolic networks of the DO patients do not present in the NO
subjects. Since the hub-networks of both NO and DO subjects were bro-
ken into small fragments at 1w after RYGB (Fig. 3), RYGB had generated
similar consequences either for the metabolite-based hub-network of
the NO subjects or for the protein-based hub-network of the DO
subjects.
Furthermore, a rebuilt hub-network mainly containing metabolites
of the NO subjects at 3 m after RYGB (Fig. 3c) was quite similar to that
at 1y after RYGB (Fig. 3d), which throws light on the PCA result that
the edge-states of NO subjects at 3 m and 1y after RYGB were grouped
in the same PC2-area (Fig. 2d). Intriguingly, the re-built hub-network
of the DO subjects at 3m after RYGB (Fig. 3g) was signiﬁcantly different
from that at 1y after RYGB (Fig. 3h). This is consistent with the observa-
tion that the edge-states of post-RYGB DO subjects at 3 m were sepa-
rated from those at 1y in the PCA map (Fig. 2d). In particular, the
amino acids were getting connected at 3 months after RYGB in the DO
individuals, which was earlier than the connection of fatty acids after
RYGB (Fig. 3g), indicating the crucial role of amino acid metabolism in
diabetes remission. This result is consistent with the previous observa-
tions of accelerated protein digestion and amino acid absorption after
meal intake after RYGB (Bojsen-Moller et al., 2015), while fasting circu-
lating concentrations of total amino acids decreased signiﬁcantly
(Laferrere et al., 2011a). Interestingly, the overall metabolic hub-network structure of the DO subjects at 1y after RYGB (Fig. 3h) looks
quite similar to that of the NO subjects at 3 m (Fig. 3c) or 1y after
RYGB (Fig. 3d). Taken together, we conclude that the DO subjects at
1y after RYGB have built a novel metabolic network similar to that of
the post-RYGB NO subjects, which could generate an improved glucose
homeostasis and result in the remission of type 2diabetes.
4. Discussion
Generally, biological networks show characteristic changes during
disease progression. Thus, to deﬁne a physiological or pathological
state is to measure a set of bio-molecules such as the concentrations
of particular RNAs, proteins or metabolites, which are called nodes in
term of network (Luonan Chen et al., 2010; Zhang et al., 2015). The
state of a biological system diﬁned by calculating the concentrations
or concentration-changes of the nodes therefore is called the node-
state (see left panel of Fig. 1d).
However, several reports indicate that the calculated node-states
may be misleading due to both high ﬂuctuations of the nodes' concen-
trations and individual variations (Chen et al., 2012; Liu et al., 2014).
In addition, many molecules/nodes may show time-dependent varia-
tions and are sensitive to small perturbations of various factors that
are irrelevant to the observed phenotypes, and thus are not reliable
markers to characterize the states of the network (Liu et al., 2016;
Zeng et al., 2016).
Based on our previous studies (Zeng et al., 2016; Zhang et al., 2015),
we developed an alternativeway to characterize biological systems by a
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which is called the edge-state (see right panel of Fig. 1d). The edges di-
rectly represent the associations or correlation between the molecules
within the bio-networks and are much more robust in contrast to the
ﬂuctuations of node concentrations (Yu et al., 2014; Zeng et al., 2016).
Therefore, an edge-state is composed of all edges of the network,
which is considered to be insensitive to various small perturbations ir-
relevant to the phenotypes. Hence, the edge-state is a reliable marker
to characterize the bio-network or physiological states of organisms.
In the present study, we showed that, based on the edge-states, the
remission-paths of both DO and NO subjects after RYGBwas clearly dif-
ferentiated (Fig. 2c and d),whereas the node-states could not deﬁne the
remission-path of the DO subjects from that of the NO subjects after
RYGB (Fig. 2a and b).
The analysis of edge-states seems to be another advantage that even
small fraction of proteins andmetabolites (e.g. 146 plasma proteins and
128metabolites in the present study) could provide clearly and deﬁned
information to characterize the physiological or pathological states
sincewe calculate themolecular associations rather than the concentra-
tions of bio-molecules. In addition, all the proteins and metabolites an-
alyzed in the present study are identiﬁed from patient plasma, which
must reﬂect the states of whole body rather than the states of particular
cells or tissues.
Recently, Boyle and colleagues have proposed an “omnigenic”model
for disease-related complex traits, “we propose that gene regulatory
networks are sufﬁciently interconnected such that all genes expressed
in disease-relevant cells are liable to affect the functions of core
disease-related genes and that most heritability can be explained by ef-
fects on genes outside core pathways” (Boyle et al., 2017). This model
fully supports our ﬁnding: “core disease-related genes” are correspond-
ing to “molecular nodes”, and “extensive interconnected gene regula-
tory networks” are corresponding to our “edge-states”. We believe
that the edges/associations among small number of bio-molecules de-
rived from plasma can be used for deﬁnition of global biological states
of the body due to the extensive interconnection of bio-molecules in a
biological system. And, just because of this reason, we ﬁrst endeavored
to establish the entire workﬂow by integrating the proteomics and
metabolomics data to illuminating the value of edge-states for this
type of complex network analysis behind gastric bypass surgery.
Based on integration of phenotype data derived from our previous
study (Bojsen-Moller et al., 2014), and the hub-network analysis
(Fig. 3) in the present study, we revealed that RYGB broke the problem-
atic molecular networks of diabetic patients and resulted in re-building
a well-connected metabolic molecular network for glucose homeosta-
sis, which was reﬂected as the unique remission-path of diabetes pa-
tients independent of weight loss (Fig. 2d).
By analyzing the re-wired hub networks in detail, we observed that
the interconnection of amino acids was signiﬁcantly increased in the
hub-networks of the post-RYGB DO subjects (Fig. 3g), whereas the
highly interconnected protein hub-networks of pre-RYGB DO subjects
(Fig. 3e)was completely disrupted after the surgery (Fig. 3f–h). This im-
plies that the RYGB-induced rebuilding the hub-network of amino acids
plays important role to establish normal glucose homeostasis of type 2
diabetes patients. Previous reports showed that serum levels of
branched-chain and aromatic amino acids (BCAAs and AAAs), including
leucine, isoleucine, valine, phenylalanine and tyrosine, were positively
correlated to insulin resistance and obesity (Laferrere et al., 2011b;
Wurtz et al., 2013). In addition, the BCAA levels were associated with
the improvement in insulin resistance independent of weight loss
after gastric bypass surgery (Shah et al., 2012). A reported 35% decrease
in fasting plasma BCAA concentrations after gastric bypass surgery wasFig. 3. Rewiring of molecular hub networks for NO and DO subjects with time-dependent state
3 months (c), and stabilized at 1 year (d); (e-h) DO hub-network was broken at 1 week of post
networks heavily composed by the metabolites of pre-RYGB NO and by the proteins of pre-RY
from 1w to 1y-state, for both post-RYGB NO and DO subjects, the metabolites-dominated netwassociated with an increase in two key BCAA catabolic enzymes, and
these changes in expression of BCAA catabolic enzymes actually en-
hanced metabolic ﬂux and increased catabolism of BCAAs after gastric
bypass surgery (She et al., 2007). Taken together, these results imply
that the most important effect of RYGB for remission of type 2 diabetes
might be to break the dysfunctional network of amino acids and then
result in reconstruction of a new metabolic network that is similar to
that of normal glucose homeostasis.
We consider the present study based on the molecular edge-states
derived fromplasmaproteins andmetabolites as a pilot study. Certainly,
further validation with larger clinical cohorts is needed. In addition, the
recovering-path of patients after RYGB is a dynamical process, and thus
detecting its tipping point before transiting to a stable state after RYGB
by dynamic network biomarker (DNB) (Chen et al., 2012; Liu et al.,
2014) is also an interesting problem for further dissolving. In addition,
the more studies with animal-models on the mechanisms of metabolic
improvement, particular rebuilding the networks of amino acids by
RYGB, are worth doing in the near future.
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